We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $604M
1-Year Est. Return 96.57%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$270M
AUM Growth
-$44.3M
Cap. Flow
-$59.3M
Cap. Flow %
-21.92%
Top 10 Hldgs %
74.66%
Holding
64
New
15
Increased
6
Reduced
6
Closed
18

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$10.4M
2
STAA icon
STAAR Surgical
STAA
+$9.86M
3
ICLR icon
Icon
ICLR
+$6.74M
4
NVAX icon
Novavax
NVAX
+$6M
5
HSKA
Heska Corp
HSKA
+$5.68M

Top Sells

Rank Stock Value
1
COR icon
Cencora
COR
+$31.3M
2
GSK icon
GSK
GSK
+$23.3M
3
SNY icon
Sanofi
SNY
+$13.6M
4
CNC icon
Centene
CNC
+$9.88M
5
SKIN icon
SkinHealth Systems
SKIN
+$7.77M

Sector Composition

Rank Sector Weight
1 Healthcare 59.82%
2 Miscellaneous 31.53%
3 Financials 8.65%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXDX
1
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$63.2M 23.36%
574,200
+242,000
+73% +$15.7M
MSAC
2
DELISTED
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
$23.4M 8.65%
2,323,000
– –
BCYC
3
Bicycle Therapeutics
BCYC
$294M
$20.2M 7.48%
683,425
– –
CI icon
4
Cigna
CI
$73.7B
$17.4M 6.45%
52,611
– –
OGN icon
5
Organon & Co
OGN
$3.61B
$16.4M 6.07%
587,836
-41,000
-7% -$1.05M
UTHR icon
6
United Therapeutics
UTHR
$22.1B
$15.3M 5.65%
54,959
+10,000
+22% +$2.52M
DGX icon
7
PUT
Quest Diagnostics
DGX
$26.8B
$14.4M 5.32%
+92,000
New +$13.2M
COR icon
8
Cencora
COR
$61.5B
$14M 5.17%
84,399
-198,000
-70% -$31.3M
MDT icon
9
Medtronic
MDT
$117B
$9.95M 3.68%
+128,000
New +$10.4M
STAA icon
10
STAAR Surgical
STAA
$1.11B
$7.63M 2.82%
+157,129
New +$9.86M
ICLR icon
11
Icon
ICLR
$13.1B
$6.6M 2.44%
+33,983
New +$6.74M
INGN icon
12
Inogen
INGN
$146M
$5.65M 2.09%
286,692
-234,603
-45% -$5.05M
AVTR icon
13
Avantor
AVTR
$9.86B
$5.27M 1.95%
+250,000
New +$5.18M
HSKA
14
DELISTED
Heska Corp
HSKA
$5.24M 1.94%
+84,309
New +$5.68M
PTGX icon
15
Protagonist Therapeutics
PTGX
$9.34B
$4.74M 1.75%
+434,635
New +$3.67M
NVAX icon
16
Novavax
NVAX
$1.53B
$3.5M 1.29%
+340,000
New +$6M
CBAY
17
DELISTED
Cymabay Therapeutics
CBAY
$3.48M 1.29%
555,610
– –
PHVS icon
18
Pharvaris
PHVS
$2.48B
$3.21M 1.19%
+285,000
New +$1.5M
MACK
19
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$2.87M 1.06%
+250,000
New +$2.06M
RETA
20
PUT
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$2.55M 0.94%
+67,000
New +$2.31M
OBIO icon
21
Orchestra BioMed
OBIO
$311M
$2.5M 0.92%
250,000
– –
EUCRU
22
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.48M 0.92%
248,674
– –
CTIC
23
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$1.98M 0.73%
+330,000
New +$1.8M
ISEE
24
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.85M 0.68%
86,400
– –
XFOR icon
25
X4 Pharmaceuticals
XFOR
$401M
$1.81M 0.67%
60,865
+13,583
+29% +$643K
1
2 3

Similar funds

EFL
ERn Financial LLC Middleton, Wisconsin $604M AUM 19.83% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $604M AUM 72.61% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $604M AUM 64.38% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
VCP
Varenne Capital Partners Paris, France $603M AUM 46.34% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Sio Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Sio Capital Management held 64 positions worth $270M, down 14% from $315M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Sio Capital Management withdrew a net $59.3M in Q4 2022, closing 18 positions and reducing 6 holdings. Its most notable exit was GSK, an estimated $23.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 64% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Sio Capital Management opened a new position in Medtronic worth $9.95M.

  • Sio Capital Management's largest Q4 2022 buy was Medtronic: 128,000 shares worth $9.95M.
  • Sio Capital Management added most to United Therapeutics in Q4 2022, an estimated $2.52M increase.
  • Sio Capital Management's biggest Q4 2022 reduction was Cencora, cutting an estimated $31.3M.
  • Sio Capital Management fully exited GSK in Q4 2022, selling an estimated $23.3M.
  • Sio Capital Management's ten largest holdings make up 75% of its $270M portfolio in Q4 2022.
  • Sio Capital Management opened 15 new positions and closed 18 in Q4 2022.
  • Sio Capital Management's portfolio value fell 14% quarter-over-quarter to $270M.

Based on Sio Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.